XenaLives, I am perplexed by your positions here. While I cannot go along with the most positive expectations from this board, I am puzzled how you seem to write off the possibility of success here, if that is your position. When I weigh the development work and available data from both the AVXL drug and the NTRP drug I lean toward the AVXL drug having a little more efficacy data to work with but both are so early I am not sure how anyone can draw any real conclusions. I am optimistic on both drugs with little to g on with both drugs. A 32 patient open label trial in Australia with mild to moderate patients is a start but barely a start. A 9 patient P2a is not even a start yet. The entire body of science shows potential for both. I have seen drugs pop up from unexpected situations out of the ashes of other attempted or approved indications and I am hoping it happens again with bryostatin. I am thrilled one will publish significant high value development data shortly to see if the hopes of many will flourish or be dashed. I am bullish on both drugs, theoretically liking the mechanism of action more with the AVXL drug a little more, though it appears to be a more subtle PD activity while being very intrigued by the NTRP company aggressive strategy to tackle severe patients displaying confidence and a more direct mechanism of action resulting from extensive years of focused research.
Are you playing the devil's advocate or just anti-bryostatin?
AI
Market Data 
Markets 
